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Abstract
Background: Chemotherapy near the end of life is an issue frequently discussed nowadays. The concern is that
chemotherapy could cause more harm than good in a palliative situation; this is even truer as the patient nears
death. The objective of our study is to evaluate the aggressiveness of patient care near the end of life by
determining how many cancer patients receive chemotherapy during their final weeks.
Methods: In a retrospective analysis of patient charts, we investigated whether cancer patients had been treated
with chemotherapy during the last four or two weeks of life. If they had, we looked at whether treatment was
ongoing or newly initiated.
Results: Out of the 119 cancer patients who died in our hospital over two years, 14 (11.7%) received chemotherapy
during the last four weeks of life, nine of whom (7.6%) in the last two weeks of life. Treatment had been ongoing
in six (5%) and newly initiated for eight (6.7%) within four weeks of death. Corresponding figures for the last two
weeks of life were seven patients (5.9%) who continued previously prescribed treatment and two (1.7%) who were
started on chemotherapy. Patients given chemotherapy during the last four weeks of life were significantly younger
than those who were not (p = 0.003).
Conclusions: Cancer patient care in our hospital is not considered overly aggressive as only 7.6% of these patients
receive chemotherapy within the last two weeks of life. To determine how aggressive care near the end of life
really is, however, we suggest evaluating newly started chemotherapy alongside ongoing treatment. As the line
between the effects (beneficience) and side effects (nonmaleficience) of chemotherapy is often very narrow,
doctors and patients have to work together to find the best way of treading this fine line.
Background
Chemotherapy near the end of life is an issue frequently
discussed nowadays. Both, patients and doctors are con-
cerned that chemotherapy could cause more harm than
good in a palliative situation. This is even truer as the
patient nears death, when the main aim of treatment is
usually palliation and not prolonging life.
Earle et al. report that the treatment of cancer patients
near the end of life is becoming more and more aggressive
[1]. According to the Health Service Research Committee
of the American Society of Clinical Oncology (ASCO),
treatment can be recommended if it improves the quality
of life in patients with metastatic cancer even though it
does not improve survival [2].
Clinical trials have shown that chemotherapy may palliate
symptoms with a resultant improvement in quality of life.
However, giving palliative chemotherapy near the end of
life, is a balancing act between clinical benefit and potential
harm in terms of side effects. Appropriately timed discon-
tinuation of chemotherapy is essential for the patient’s qual-
ity of life. The ASCO Quality Oncology Practice Initiative
(QOPI) included “Chemotherapy administered within the
last two weeks of life (lower score-better)” as a benchmark
for improving clinical practice [3].
Questions of particular interest are:
– What percentage of patients can receive
chemotherapy near the end of life in such a way that
care is not overly aggressive – and how long before
death should chemotherapy be stopped?
– What constitutes a good treatment decision and
who is involved in the decision- making process?
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When ascertaining the number of patients receiving
chemotherapy near the end of life, several authors have
focused on the four weeks before death. In our study,
we determined not only how many patients had been
given chemotherapy within the last four weeks of life,
but also how many had been treated within the last
two weeks, as indicated by QOPI [3]. We made a dis-
tinction between ongoing treatment and newly initi-
ated chemotherapy.
Methods
Our hospital is a midsize public hospital in a city in
Switzerland; cancer patients are cared for and treated as
outpatients or inpatients by a team of oncologists. Using
computerised medical records and manual searches in
charts, we included all patients whose main diagnosis
was cancer and who died in our hospital in 2006 or
2007. Our rationale for selecting patients with a main
diagnosis of cancer was that, in theory, only these pa-
tients would have had an indication for chemotherapy.
We concentrated on chemotherapy and did not analyse
other treatment, such as radiotherapy or surgery.
Data gathered for our retrospective analysis included
the following:
type of cancer
age of patients
sex of patients
chemotherapy during the last four weeks of life
– ongoing chemotherapy
– start of new chemotherapy
chemotherapy during the last two weeks of life
ongoing chemotherapy
start of new chemotherapy
All data were anonymised.
To calculate a possible correlation between the age or
sex of a patient and the probability to be given chemother-
apy near the end of life we used the Fisher’s exact test.
The Ethics Committee of the Canton of Zurich, Switzerland,
approved this project.
We compared our results with those found in the lit-
erature, in order to discuss them from an ethical point
of view in the light of other publications. At the same
time, we reviewed the decision-making process.
Results
The analysis took data from the clinical charts of 119 pa-
tients who died of cancer in our hospital during 2006 or
2007: 62 in 2006 and 57 in 2007.
Patients’ characteristics
The median age of all 119 patients was 75 (range 48–94)
years; 48 (40%) of all patients were women, 71 (60%) were
men. The most frequent diagnosis in our patients was
gastrointestinal cancer (44/119 patients; 37%), followed by
lung cancer (36/119; 30%). Figures for gynaecological can-
cers (12/119; 10%) and urogenital cancers (7/119 patients;
6%) were lower in our patient population than would gen-
erally be expected, as our hospital has no gynaecology or
urology department. Nine (8%) patients were suffering
from lymphoma, leukaemia or myeloma, and 11 (9%) pa-
tients from other malignancies (Table 1).
Chemotherapy near the end of life
During the last four weeks of life (day −28 until death)
14 patients (11.7%) were treated with chemotherapy.
Six patients (5%) continued with their previously pre-
scribed treatment and eight patients (6.7%) were started
on chemotherapy.
During the last two weeks of life (day −14 until death)
nine patients (7.6%) were given chemotherapy. Seven
patients (5.9%) were already on chemotherapy, while two
patients (1.7%) were started on chemotherapy during this
time (Table 2).
Figure 1 shows the treatment sequence (continued,
started, stopped) during the last weeks of life.
All chemotherapy was intended for the palliative care
of patients whose cancer was considered incurable, with
the main aims of relieving symptoms and improving the
quality of life.
Characteristics of patients receiving chemotherapy near
the end of life
Among the 14 patients who received chemotherapy dur-
ing the last four weeks of life, 11 (79%) were younger than
75 ( =median age); six (43%) were women.
Table 1 Patients‘ characteristics (N = 119)
Typ of cancer Numbers %
Gastrointestinal 44 37
Lung 36 30
Gynaecological 12 10
Lymphoma/leukaemia/myeloma 9 8
Urogenital 7 6
Others 11 9
Gender Numbers %
Female 48 40
Male 71 60
Ethnicity Numbers %
Caucasian 119 100
Other 0 0
Age Range Median
Years 48-94 75
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We carried out a statistical analysis to examine pos-
sible associations between the patient’s age or sex and
the fact that they were given chemotherapy during the
last four weeks of life. Fisher’s exact test gave a highly
significant p-value of 0.003 with respect of age. This
means that the patients in our cohort given chemotherapy
near the end of their lives (last four weeks) were signifi-
cantly younger than those not receiving any chemother-
apy. However, the patient’s sex had no effect on whether
or not they were given chemotherapy near the end of life
(p = 1.0) (Table 3).
Among the 14 patients given chemotherapy near the
end of life, primary cancer sites were gastrointestinal in
four, lung in three, myeloma or leukaemia in three, uro-
genital in two, gynaecological in one, and other in one.
Comparison with published results on chemotherapy of
cancer patients at the end of life
Out of the five published studies, three analysed the situ-
ation concerning chemotherapy during the last four
weeks of life and gave figures of between 7.3% and
18.8% for all cancer patients (our result: 11.7%). Four pa-
pers also reported on chemotherapy given during the
last two weeks of life, with percentages ranging from
4.2% to 11.6% (our result: 7.6%) (Table 4).
Braga et al. [4] determined that 4.7% of all cancer patients
had been started on chemotherapy within four weeks of
death (our result: 6.7%). None of the authors investigated
how many patients had received chemotherapy beginning
during the last two weeks of life (our result: 1.7%).
Discussion
This is the first study from Switzerland on the aggres-
siveness of cancer care in the last four/two weeks of life.
In a retrospective analysis of 119 clinical charts we de-
termined the number of cancer patients in our Zurich
municipal hospital who received chemotherapy near the
end of life.
During the last four weeks (28 days) of life, 14 patients
(11.7%) were given chemotherapy: ongoing treatment in
six patients (5%) and newly initiated chemotherapy in
eight patients (6.7%).
Figure 1 Treatment sequence (continued, started, stopped) during the last weeks of life.
Table 2 Chemotherapy at the end of life (last four and
last two weeks)
N = 119 Last 4 weeks Last 2 weeks
New chemotherapy 8 (6.7%) 2 (1.7%)
Ongoing chemotherapy 6 (5%) 7 (5.9%)
Total 14 (11.7%) 9 (7.6%)
Table 3 Age and sex of patients given or not receiving
chemotherapy during the last four weeks of life
Chemotherapy during the
last four weeks of life
p value
Fisher’s
exact testYes
(14 = 100%)
No
(105 = 100%)
Age < 75 y 11 (79%) 37 (35%) 0.003
≥ 75 y 3 (21%) 68 (65%)
Sex Male 8 (57%) 63 (60%) 1.0
Female 6 (43%) 42 (40%)
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During the last two weeks (14 days) of life, nine pa-
tients (7.6%) received chemotherapy: seven (5.9%) con-
tinued with previously prescribed treatment, while two
(1.7%) were started on chemotherapy.
The number of patients analysed in this study is rela-
tively small (119), and the study sample is just from one
hospital site. This means that the generalizability of the
results of this study is limited. But still the results are
important, as worldwide there is only a very limited
number of studies on this issue.
A literature search revealed five studies presenting
analyses comparable to our own. However, none of them
made a distinction between ongoing and newly initiated
chemotherapy, as we did.
Three of these five studies found in the literature re-
ported the number of cancer patients on chemotherapy
during the last four weeks of life [4-6], ranging from
7.3% to 18.8%. Only one author determined the cases
(4.7%) in which chemotherapy had been started during
this period [4].
Four of the five studies also reported on chemotherapy
during the last two weeks of life [4,6-8], with figures ran-
ging from 4.2% to 11.6% of patients, but none of them de-
termined how often chemotherapy was actually started
within two weeks of death.
Earle et al. generated and evaluated quality indicators
for end-of-life cancer care, through a combination of lit-
erature reviews, focus groups, and assessment by an ex-
pert panel [9]. One of their three major concepts of poor
quality end-of-life care is administering chemotherapy
very close to death.
The same working group later published results of
benchmarking assessments [10], concluding that “the
analysis of SEER-Medicare claims suggests that health care
systems not providing overly aggressive care would be ones
in which less than 10% of patients receive chemotherapy in
the last 14 days of life”. The findings of Kao et al. [6] with
4.3% and Barbera with 4.2% meet this criterion [7], as
do ours with 7.6%. Earle et al. [8] describe an increasing
number of patients receiving chemotherapy during the
last two weeks of life from 9.7% in 1993 to 11.6% in 1999.
In our opinion, however, there is an important differ-
ence between ongoing and new chemotherapy. The rea-
son for starting chemotherapy is always to treat cancer;
it is always an active procedure. On the contrary, the
reasons for not stopping chemotherapy can vary. For
one thing patients may die from causes other than can-
cer, sometimes unexpectedly. On these grounds, starting
new chemotherapy near the end of life is a more aggres-
sive approach than simply not discontinuing ongoing
treatment.
To determine how aggressive end-of-life care for can-
cer patients really is, we suggest that newly initiated
chemotherapy should be evaluated separately from on-
going treatment.
And last but not least, the final weeks of life can be
analysed only in retrospect. At the start of treatment, as
well as during the treatment process, it is not always
easy to estimate the lifetime remaining.
How does the decision-making process concerning
chemotherapy near the end of life in fact evolve? Who
decides about treatment in palliative cancer care, especially
when the patient is near death? What are the prerequisites
for considering chemotherapy near the end of life?
For doctors, the first prerequisite for chemotherapy is,
of course, that we are dealing with a tumour that is sen-
sitive to cytostatic treatment. The second one is that we
can expect to see a reasonably rapid response in ad-
vanced stages of the disease. And we always have to take
the patient’s general condition and comorbidities into
account. For both doctors and patients, reports mention
younger patient age as a predictor of the likely use of
chemotherapy [4,11]. In our analysis, the patients who
were treated with chemotherapy within the last four or
two weeks of life were significantly younger than those
who were not (p = 0.003).
The basics of good treatment decisions are the patient’s
wishes and the doctor’s recommendations; functional
Table 4 Summary of reports in the literature concerning chemotherapy near the end of life compared with our own results
Author Näppä Earle Kao Braga Barbera Our results
Country Sweden USA Canada Australia Portugal Canada Switzerland
No of patients 1200 215′848 747 639 21323 119
Period analysed (years) 1 10 2 1 1 2
Median age (years) 65 ≥ 65 67 61 72 75
Sex f/m (%) 44/56 NA 44/56 61/39 47/53 40/60
Chemotherapy in last 4 weeks (%) 7.3 NA 9.8 18.8 NA 11.7
4.7 new 6.7 new
Chemotherapy in last 2 weeks (%) NA 9.7-11.6 4.3 10.7 4.2 7.6
1.7 new
Näppä et al. [5], Kao et al. [6], Braga et al. [4], Barbera [7], Earle et al. [8].
Adam et al. BMC Palliative Care 2014, 13:26 Page 4 of 5
http://www.biomedcentral.com/1472-684X/13/26
communication between doctor and patient is essen-
tial. We have to be aware that communication is more
than just delivering information [12]; it aims primarily
to establish a relationship. It is important for patients
to obtain transparent and useful information and they
need guidance in understanding the issues involved.
On the other hand, the patient’s individual wishes,
preferences and moral concepts have to be respected.
Both patient and doctor have to participate in this
shared decision-making process [13]. In their own
ways, both are experts; doctors know more about the
theoretical context of a disease, but patients know how
they feel actually having it. In a shared decision
making-process, patient and doctor act as partners.
The line between effects and side effects of chemo-
therapy is often very narrow. In making treatment deci-
sions in palliative cancer care, and especially near the
end of life, we always have to bear the patient’s quality of
life in mind. Patients have to tell us what quality of life
means for them, as only they can know.
In accordance with bioethical principles, as published
by Beauchamp and Childress [14], we do, of course, al-
ways keep beneficience in mind when we think about
chemotherapy. We want patients to benefit from treat-
ment. In palliative situations, however, the question is how
much can we accept in the way of side effects when our
aim is to help the patient? Treading the fine line between
beneficience and nonmaleficience, between the effects of
chemotherapy and its side effects, is a delicate balancing
act. Only by consciously and responsibly discussing the
matter with patients, and by respecting their wishes and
their autonomy, can this balance be achieved.
Conclusions
Cancer patient care in our hospital is not considered overly
aggressive as only 7.6% of these patients receive chemo-
therapy within the last two weeks of life. To determine
how aggressive care near the end of life really is, how-
ever, we suggest evaluating newly started chemotherapy
alongside ongoing treatment. As the line between the
effects (beneficience) and side effects (nonmaleficience)
of chemotherapy is often very narrow, doctors and
patients have to work together to find the best way of
treading this fine line.
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